Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:57 UTC |
---|
HMDB ID | HMDB0015364 |
---|
Secondary Accession Numbers | - HMDB0030049
- HMDB15364
- HMDB30049
|
---|
Metabolite Identification |
---|
Common Name | Dexamethasone |
---|
Description | Dexamethasone is only found in individuals that have used or taken this drug. It is an anti-inflammatory 9-fluoro-glucocorticoid. Dexamethasone is a glucocorticoid agonist. It is used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions. Dexamethasone can be used in the context of congenital adrenal hyperplasia, to prevent virilisation of a female fetus. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Dexamethasone has been shown to exhibit anesthetic, anti-microbial, appetite stimulant, muscle building and sedative functions (PMID 16571981 , 19842390 , 11563572 , 20080405 , 2898201 ). Its potency is about 20-30 times that of hydrocortisone and 4-5 times of prednisone. |
---|
Structure | [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 |
---|
Synonyms | Value | Source |
---|
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone | ChEBI | 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol | ChEBI | 9alpha-Fluoro-16alpha-methylprednisolone | ChEBI | Decadron | ChEBI | Dexametasona | ChEBI | Dexamethasonum | ChEBI | Maxidex | Kegg | 1-Dehydro-16a-methyl-9a-fluorohydrocortisone | Generator | 1-Dehydro-16α-methyl-9α-fluorohydrocortisone | Generator | 16a-Methyl-9a-fluoro-1-dehydrocortisol | Generator | 16Α-methyl-9α-fluoro-1-dehydrocortisol | Generator | 9a-Fluoro-16a-methylprednisolone | Generator | 9Α-fluoro-16α-methylprednisolone | Generator | 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone | HMDB | 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol | HMDB | 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone | HMDB | 16-alpha-Methyl-9-alpha-fluoroprednisolone | HMDB | 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol | HMDB | 16alpha -Methyl-9alpha -fluoroprednisolone | HMDB | 16alpha-Methyl-9alpha-fluoroprednisolone | HMDB | 9-alpha-Fluoro-16-alpha-methylprednisolone | HMDB | 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione | HMDB | 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione | HMDB | 9-Fluoro-16-methylprednisolone | HMDB | 9a-Fluoro-16BETA-methylprednisolone | HMDB | 9alpha -Fluoro-16alpha -methylprednisolone | HMDB | 9alpha-Fluoro-16alpha-methyl-prednisolone | HMDB | Aeroseb-D | HMDB | Aeroseb-dex | HMDB | Ak dex OPH otic soln 0.1% | HMDB | alpha -Fluoro-16-alpha -methylcortisol | HMDB | Anaflogistico | HMDB | Aphtasolon | HMDB | Apo-dexamethasone | HMDB | Auxiron | HMDB | Azimycin (veterinary) | HMDB | Azium | HMDB | Azium (veterinary) | HMDB | Bisu DS | HMDB | Calonat | HMDB | Corson | HMDB | Corsone | HMDB | Cortisumman | HMDB | Decacortin | HMDB | Decaderm | HMDB | Decagel | HMDB | Decalix | HMDB | Decasone | HMDB | Decaspray | HMDB | Dectancyl | HMDB | Dekacort | HMDB | Delta1-9alpha-Fluoro-16alpha-methylcortisol | HMDB | Deltafluorene | HMDB | Dergramin | HMDB | Desadrene | HMDB | Desametasone | HMDB | Desamethasone | HMDB | Desameton | HMDB | Deseronil | HMDB | DEX | HMDB | Dex-ide | HMDB | DEXA | HMDB | Dexa mamallet | HMDB | Dexa-cortidelt | HMDB | Dexa-cortisyl | HMDB | Dexa-scheroson | HMDB | Dexa-sine | HMDB | Dexacidin | HMDB | Dexacort | HMDB | Dexacortal | HMDB | Dexacortin | HMDB | Dexadeltone | HMDB | Dexafarma | HMDB | Dexalona | HMDB | Dexametasone | HMDB | Dexameth | HMDB | Dexamethansone | HMDB | Dexamethasone acetate | HMDB | Dexamethasone alcohol | HMDB | Dexamethasone base | HMDB | Dexamethasone intensol | HMDB | Dexamethasone sodium phosphate | HMDB | Dexamethasone-omega | HMDB | Dexamethazone | HMDB | Dexapolcort | HMDB | Dexapos | HMDB | Dexaprol | HMDB | Dexason | HMDB | Dexasone | HMDB | Dexasone 0.5MG | HMDB | Dexasone 0.75MG | HMDB | Dexasone 4MG | HMDB | Dexasporin | HMDB | Dexinolon | HMDB | Dexinoral | HMDB | Dexone | HMDB | DEXONE 0.5 | HMDB | DEXONE 0.75 | HMDB | DEXONE 1.5 | HMDB | DEXONE 4 | HMDB | Dextelan | HMDB | Dezone | HMDB | Dinormon | HMDB | DXM | HMDB | DXMS | HMDB | Fluormethylprednisolone | HMDB | Fortecortin | HMDB | Gammacorten | HMDB | Hexadecadrol | HMDB | Hexadrol | HMDB | Hexadrol elixir | HMDB | HL-Dex | HMDB | Isopto-dex | HMDB | Lokalison F | HMDB | Loverine | HMDB | Luxazone | HMDB | Maxidex ont 0.1% | HMDB | Maxidex sus 0.1% | HMDB | Maxitrol | HMDB | Mediamethasone | HMDB | Methylfluorprednisolone | HMDB | Mexidex | HMDB | Mymethasone | HMDB | Naquasone (veterinary) | HMDB | Neomycin and polymyxin b sulfates and dexamethasone | HMDB | Neomycin and polymyxin b sulphates and dexamethasone | HMDB | NSC 34521 | HMDB | Ocu-trol | HMDB | Oradexon | HMDB | Pet derm III | HMDB | PHL-Dexamethasone | HMDB | PMS Dexamethasone elixir 0.5mg/5ML | HMDB | PMS-Dexamethasone | HMDB | Policort | HMDB | Prednisolon F | HMDB | Prednisolone F | HMDB | Prodex | HMDB | Sandoz dexamethasone | HMDB | SK-Dexamethasone | HMDB | Spoloven | HMDB | Sunia sol D | HMDB | Superprednol | HMDB | Tobradex | HMDB | Tobramycin and dexamethasone | HMDB | Tresaderm (veterinary) | HMDB | Turbinaire | HMDB | Visumetazone | HMDB | Millicorten | HMDB | Decaject-l.a. | HMDB | Decameth | HMDB | Dexpak | HMDB | Foy brand OF dexamethasone | HMDB | Merz brand 1 OF dexamethasone | HMDB | Merz brand 2 OF dexamethasone | HMDB | ICN brand OF dexamethasone | HMDB | Alcon brand OF dexamethasone | HMDB | Decaject | HMDB | Decaject l.a. | HMDB | ECR brand OF dexamethasone | HMDB | Merck brand OF dexamethasone | HMDB |
|
---|
Chemical Formula | C22H29FO5 |
---|
Average Molecular Weight | 392.4611 |
---|
Monoisotopic Molecular Weight | 392.199902243 |
---|
IUPAC Name | (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one |
---|
Traditional Name | dexamethasone |
---|
CAS Registry Number | 50-02-2 |
---|
SMILES | [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |
---|
InChI Identifier | InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 |
---|
InChI Key | UREBDLICKHMUKA-CXSFZGCWSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Hydroxysteroids |
---|
Direct Parent | 21-hydroxysteroids |
---|
Alternative Parents | |
---|
Substituents | - Progestogin-skeleton
- 21-hydroxysteroid
- Pregnane-skeleton
- 20-oxosteroid
- 3-oxo-delta-1,4-steroid
- 3-oxosteroid
- 17-hydroxysteroid
- 11-hydroxysteroid
- 11-beta-hydroxysteroid
- 9-halo-steroid
- Halo-steroid
- Oxosteroid
- Delta-1,4-steroid
- Alpha-hydroxy ketone
- Cyclic alcohol
- Tertiary alcohol
- Ketone
- Fluorohydrin
- Halohydrin
- Secondary alcohol
- Cyclic ketone
- Organooxygen compound
- Alcohol
- Primary alcohol
- Hydrocarbon derivative
- Organic oxide
- Carbonyl group
- Organic oxygen compound
- Alkyl halide
- Alkyl fluoride
- Organohalogen compound
- Organofluoride
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 262 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.05 g/L | Not Available | LogP | 1.1 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Dexamethasone,1TMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=O)CO | 3321.2 | Semi standard non polar | 33892256 | Dexamethasone,1TMS,isomer #2 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO[Si](C)(C)C | 3331.1 | Semi standard non polar | 33892256 | Dexamethasone,1TMS,isomer #3 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O)C(=O)CO | 3264.5 | Semi standard non polar | 33892256 | Dexamethasone,1TMS,isomer #4 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=CO)O[Si](C)(C)C | 3258.9 | Semi standard non polar | 33892256 | Dexamethasone,2TMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=O)CO | 3245.0 | Semi standard non polar | 33892256 | Dexamethasone,2TMS,isomer #2 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=O)CO[Si](C)(C)C | 3353.3 | Semi standard non polar | 33892256 | Dexamethasone,2TMS,isomer #3 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=CO)O[Si](C)(C)C | 3254.6 | Semi standard non polar | 33892256 | Dexamethasone,2TMS,isomer #4 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O)C(=O)CO[Si](C)(C)C | 3236.6 | Semi standard non polar | 33892256 | Dexamethasone,2TMS,isomer #5 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=CO[Si](C)(C)C)O[Si](C)(C)C | 3243.7 | Semi standard non polar | 33892256 | Dexamethasone,2TMS,isomer #6 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O)C(=CO)O[Si](C)(C)C | 3184.7 | Semi standard non polar | 33892256 | Dexamethasone,3TMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=O)CO[Si](C)(C)C | 3271.4 | Semi standard non polar | 33892256 | Dexamethasone,3TMS,isomer #2 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=CO)O[Si](C)(C)C | 3168.7 | Semi standard non polar | 33892256 | Dexamethasone,3TMS,isomer #3 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=CO[Si](C)(C)C)O[Si](C)(C)C | 3245.9 | Semi standard non polar | 33892256 | Dexamethasone,3TMS,isomer #4 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O)C(=CO[Si](C)(C)C)O[Si](C)(C)C | 3156.5 | Semi standard non polar | 33892256 | Dexamethasone,4TMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=CO[Si](C)(C)C)O[Si](C)(C)C | 3181.6 | Semi standard non polar | 33892256 | Dexamethasone,4TMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=CO[Si](C)(C)C)O[Si](C)(C)C | 3283.3 | Standard non polar | 33892256 | Dexamethasone,4TMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C)C(=CO[Si](C)(C)C)O[Si](C)(C)C | 3389.7 | Standard polar | 33892256 | Dexamethasone,1TBDMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=O)CO | 3545.4 | Semi standard non polar | 33892256 | Dexamethasone,1TBDMS,isomer #2 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO[Si](C)(C)C(C)(C)C | 3580.6 | Semi standard non polar | 33892256 | Dexamethasone,1TBDMS,isomer #3 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O)C(=O)CO | 3480.7 | Semi standard non polar | 33892256 | Dexamethasone,1TBDMS,isomer #4 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=CO)O[Si](C)(C)C(C)(C)C | 3491.2 | Semi standard non polar | 33892256 | Dexamethasone,2TBDMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=O)CO | 3698.1 | Semi standard non polar | 33892256 | Dexamethasone,2TBDMS,isomer #2 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=O)CO[Si](C)(C)C(C)(C)C | 3816.0 | Semi standard non polar | 33892256 | Dexamethasone,2TBDMS,isomer #3 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=CO)O[Si](C)(C)C(C)(C)C | 3721.3 | Semi standard non polar | 33892256 | Dexamethasone,2TBDMS,isomer #4 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O)C(=O)CO[Si](C)(C)C(C)(C)C | 3721.2 | Semi standard non polar | 33892256 | Dexamethasone,2TBDMS,isomer #5 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3694.2 | Semi standard non polar | 33892256 | Dexamethasone,2TBDMS,isomer #6 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O)C(=CO)O[Si](C)(C)C(C)(C)C | 3640.1 | Semi standard non polar | 33892256 | Dexamethasone,3TBDMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=O)CO[Si](C)(C)C(C)(C)C | 3948.1 | Semi standard non polar | 33892256 | Dexamethasone,3TBDMS,isomer #2 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=CO)O[Si](C)(C)C(C)(C)C | 3866.9 | Semi standard non polar | 33892256 | Dexamethasone,3TBDMS,isomer #3 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3926.7 | Semi standard non polar | 33892256 | Dexamethasone,3TBDMS,isomer #4 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3819.9 | Semi standard non polar | 33892256 | Dexamethasone,4TBDMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4030.4 | Semi standard non polar | 33892256 | Dexamethasone,4TBDMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4085.1 | Standard non polar | 33892256 | Dexamethasone,4TBDMS,isomer #1 | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@@]1(O[Si](C)(C)C(C)(C)C)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3651.1 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Dexamethasone GC-MS (Non-derivatized) - 70eV, Positive | splash10-02ai-2923000000-e31987dc12e5a702a42e | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dexamethasone GC-MS (3 TMS) - 70eV, Positive | splash10-0006-2414490000-490d5cc0ad1eca76d44e | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dexamethasone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-01ot-0904000000-dbbc479b104fbe981ce7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-0002-0903000000-c84b561c97b1277fed56 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-0002-0903000000-b498846e21073040b905 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-0002-0900000000-b04e175289861dc518f1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-0002-0900000000-b04e175289861dc518f1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-01ot-0904000000-dbbc479b104fbe981ce7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-0002-0903000000-c84b561c97b1277fed56 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , negative-QTOF | splash10-0002-0903000000-b498846e21073040b905 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone 40V, Negative-QTOF | splash10-002f-0492000000-0da6f331454c287b0c18 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone 55V, Negative-QTOF | splash10-0002-0900000000-b04e175289861dc518f1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone 55V, Negative-QTOF | splash10-0002-0903000000-b498846e21073040b905 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone 35V, Negative-QTOF | splash10-0002-0903000000-c84b561c97b1277fed56 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone 10V, Negative-QTOF | splash10-03di-0009000000-7adbbb206239045cde50 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone 20V, Negative-QTOF | splash10-03di-0009000000-972ed7af2cdb3ddac1a0 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-qTof , Positive-QTOF | splash10-0a4r-0696000000-1df7921eb1369fef69c4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-qTof , Positive-QTOF | splash10-00dj-3960000000-e9ee044790c0655981b1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-QTOF , positive-QTOF | splash10-006w-0719000000-d4feef3f83ca022aa94d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-QTOF , positive-QTOF | splash10-0002-0913000000-3c8e5afb526637f1e822 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-QTOF , positive-QTOF | splash10-0002-0910000000-57f268bed9b190ee6066 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-QTOF , positive-QTOF | splash10-0002-0900000000-cfdda545a27ec16c8b76 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-QTOF , positive-QTOF | splash10-0002-0900000000-c70817ad99741f01b675 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , positive-QTOF | splash10-00di-0009000000-ecbabc9fe90444b14afe | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , positive-QTOF | splash10-05fr-0019000000-4161bdd8f3deed25b9bc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , positive-QTOF | splash10-002r-0594000000-bf4495b7906d53ad019d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dexamethasone LC-ESI-ITFT , positive-QTOF | splash10-00ds-0980000000-c4e88ec70fa28252f6f7 | 2017-09-14 | HMDB team, MONA | View Spectrum |
|
---|
General References | - Bisgaard T: Analgesic treatment after laparoscopic cholecystectomy: a critical assessment of the evidence. Anesthesiology. 2006 Apr;104(4):835-46. [PubMed:16571981 ]
- Chisti MJ, Bardhan PK, Huq S, Khan WA, Khan AM, Sharifuzzaman, Salam MA: High-dose intravenous dexamethasone in the management of diarrheal patients with enteric fever and encephalopathy. Southeast Asian J Trop Med Public Health. 2009 Sep;40(5):1065-73. [PubMed:19842390 ]
- Ross DD, Alexander CS: Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting. Am Fam Physician. 2001 Sep 1;64(5):807-14. [PubMed:11563572 ]
- Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, Jamieson CA: Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. 2010 Feb;20(2):111-21. doi: 10.1016/j.nmd.2009.12.003. Epub 2010 Jan 18. [PubMed:20080405 ]
- Liu JZ, Huang YH, Hand PJ: Effects of dexamethasone on electroacupuncture analgesia and central nervous system metabolism. Acupunct Electrother Res. 1988;13(1):9-23. [PubMed:2898201 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- (). Yannai, Shmuel. (2004) Dictionary of food compounds with CD-ROM: Additives, flavors, and ingredients. Boca Raton: Chapman & Hall/CRC.. .
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
---|